{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:47:58Z","timestamp":1781920078352,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jaad.2023.02.058","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:49:58Z","timestamp":1679489398000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome\/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts"],"prefix":"10.1016","volume":"89","author":[{"given":"Ting","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Fan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jaad.2023.02.058_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2023.02.058_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165933","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using National Health Insurance Database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.058_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1060028014560012","article-title":"Corticosteroids in Stevens-Johnson Syndrome\/toxic epidermal necrolysis: current evidence and implications for future research","volume":"49","author":"Law","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12758","article-title":"Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"32","author":"Gilbert","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.02.058_bib7","doi-asserted-by":"crossref","first-page":"750173","DOI":"10.3389\/fphar.2021.750173","article-title":"Intravenous immunoglobulin combined with corticosteroids for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a propensity-matched retrospective study in China","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.058_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000177430.89645.6d","article-title":"Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome","volume":"45","author":"Hynes","year":"2005","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"12","key":"10.1016\/j.jaad.2023.02.058_bib12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.058_bib17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.058_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/pde.13778","article-title":"Pediatric toxic epidermal necrolysis treated successfully with infliximab","volume":"36","author":"Chafranska","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib19","first-page":"61","article-title":"Toxic epidermal necrolysis successfully treated with infliximab","volume":"23","author":"Z\u00e1rate-Correa","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.058_bib26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ecco-jcc\/jjz209","article-title":"Belgian IBD research group [BIRD] position statement 2019 on the use of adalimumab biosimilars in inflammatory bowel diseases","volume":"14","author":"Somers","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2023.02.058_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","article-title":"Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"38","author":"Noe","year":"2020","journal-title":"Clin Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.02.058_bib29","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/1346-8138.15490","article-title":"Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"47","author":"Torres-Navarro","year":"2020","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.058_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1684\/ejd.2020.3883","article-title":"A new case series on etanercept treatment for toxic epidermal necrolysis","volume":"30","author":"Paradisi","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.02.058_bib31","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.12788\/cutis.0288","article-title":"Efficacy of etanercept in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"107","author":"Dreyer","year":"2021","journal-title":"Cutis"},{"issue":"8","key":"10.1016\/j.jaad.2023.02.058_bib32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamadermatol.2019.3731","article-title":"Use of etanercept in a series of pediatric patients with Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum disease","volume":"156","author":"Eliades","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.02.058_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ajd.13911","article-title":"Highlighting adalimumab as a treatment option for systemic treatment of toxic epidermal necrolysis: a case series from a tertiary specialised burns centre","volume":"63","author":"Kherlopian","year":"2022","journal-title":"Australas J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.02.058_bib34","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.burns.2018.12.018","article-title":"Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"45","author":"Pham","year":"2019","journal-title":"Burns"},{"issue":"6","key":"10.1016\/j.jaad.2023.02.058_bib35","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jaad.2022.01.039","article-title":"Inhibition of tumor necrosis\u00a0factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","volume":"86","author":"Ao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.02.058_bib36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000338202","article-title":"Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin","volume":"224","author":"Gaitanis","year":"2012","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","article-title":"TNFalpha blockade in human diseases: mechanisms and future directions","volume":"126","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2023.02.058_bib39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related Infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.jaad.2023.02.058_bib40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/all.14022","article-title":"Apolipoprotein A-IV acts as an endogenous anti-inflammatory protein and is reduced in treatment-na\u00efve allergic patients and allergen-challenged mice","volume":"75","author":"Roula","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jaad.2023.02.058_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2005.03.002","article-title":"Immune-regulation of the apolipoprotein A-I\/C-III\/A-IV gene cluster in experimental inflammation","volume":"31","author":"Navarro","year":"2005","journal-title":"Cytokine"},{"issue":"600","key":"10.1016\/j.jaad.2023.02.058_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300498X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300498X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:23:41Z","timestamp":1759274621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222300498X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S019096222300498X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.058","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome\/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}